How to buy Ocugen shares
Own Ocugen shares in just a few minutes.
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Ocugen, Inc is a biotechnology business with stocks listed in the US. Ocugen shares (OCGN) are listed on the NASDAQ and all prices are listed in US Dollars. Here's how to invest if you're based in Australia.
How to buy shares in Ocugen
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Ocugen. Find the share by name or ticker symbol: OCGN. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Ocugen reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Ocugen, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Ocugen. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
🧪How we chose these brokersFor our Top Picks, we compared our Finder partners using a proprietary algorithm in August 2020. Keep in mind that our top picks may not always be the best for you, and you're encouraged to compare for yourself to find one that works for you. Read our full methodology here to find out more.
Ocugen share priceUse our graph to track the performance of OCGN stocks over time.
Ocugen shares at a glance
|52-week range||US$0.185 - US$14.59|
|50-day moving average||US$5.0276|
|200-day moving average||US$1.5967|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||US$-4.8349|
Compare share trading platforms
Is it a good time to buy Ocugen stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Is Ocugen under- or over-valued?
Valuing Ocugen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ocugen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Ocugen's P/E ratio
Ocugen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Ocugen shares trade at around 0x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Gross profit TTM||US$0|
|Return on assets TTM||-38.66%|
|Return on equity TTM||-850.6%|
|Market capitalisation||US$1.6 billion|
TTM: trailing 12 months
Shorting Ocugen shares
There are currently 11.3 million Ocugen shares held short by investors – that's known as Ocugen's "short interest". This figure is 23.4% down from 14.8 million last month.
There are a few different ways that this level of interest in shorting Ocugen shares can be evaluated.
Ocugen's "short interest ratio" (SIR)
Ocugen's "short interest ratio" (SIR) is the quantity of Ocugen shares currently shorted divided by the average quantity of Ocugen shares traded daily (recently around 37.8 million). Ocugen's SIR currently stands at 0.3. In other words for every 100,000 Ocugen shares traded daily on the market, roughly 300 shares are currently held short.
However Ocugen's short interest can also be evaluated against the total number of Ocugen shares, or, against the total number of tradable Ocugen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ocugen's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Ocugen shares in existence, roughly 70 shares are currently held short) or 0.0723% of the tradable shares (for every 100,000 tradable Ocugen shares, roughly 72 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Ocugen.
Find out more about how you can short Ocugen stock.
Ocugen share dividends
We're not expecting Ocugen to pay a dividend over the next 12 months.
Have Ocugen's shares ever split?
Ocugen's shares were split on a 1:60 basis on 30 September 2019. So if you had owned 60 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Ocugen shares – just the quantity. However, indirectly, the new 5900% higher share price could have impacted the market appetite for Ocugen shares which in turn could have impacted Ocugen's share price.
Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of transformative therapies to cure blindness diseases. The company's pipeline product includes OCU200, a novel fusion protein that is in preclinical development stage for the treatment of wet AMD, diabetic retinopathy, and diabetic macular edema; OCU400 to treat retinitis pigmentosa, a group of rare genetic disorders; and OCU410, which is in preclinical development stage for the treatment of dry AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
Frequently asked questions
More guides on Finder
American Express Platinum Business Card
From Membership Rewards Points to savings on first and business class flights, this charge card is packed with features to help you manage business spending.
Best bed sheets in Australia
From the best sheets for summer to the most luxurious threads, these are the seven best bed sheets you can get in Australia right now.
How to buy Bumble shares from Australia
Everything we know about the Bumble IPO, plus information on how to buy in.
How to buy Ocugen shares
Steps to owning and managing MicroStrategy shares.
How to buy shares in Superhero
Everything we know about the Superhero IPO, plus information on how to buy in.
How to buy Kuaishou shares from Australia
Everything we know about the Kuaishou IPO, plus information on how to buy in.
How to invest in the Coinbase (OCGN.US) IPO
Everything we know about the Coinbase IPO, plus information on how to buy in.
How to invest in the Databricks (OCGN.US) IPO
Everything we know about the Databricks IPO, plus information on how to buy in.
How to buy Ocugen shares
Steps to owning and managing Ligand Pharmaceuticals shares.
Alternatives to Robinhood in Australia
You can't access Robinhood in Australia, so here are five low-cost alternatives to trade US stocks.
Ask an Expert